JP2021532085A5 - - Google Patents

Info

Publication number
JP2021532085A5
JP2021532085A5 JP2021500801A JP2021500801A JP2021532085A5 JP 2021532085 A5 JP2021532085 A5 JP 2021532085A5 JP 2021500801 A JP2021500801 A JP 2021500801A JP 2021500801 A JP2021500801 A JP 2021500801A JP 2021532085 A5 JP2021532085 A5 JP 2021532085A5
Authority
JP
Japan
Prior art keywords
domain
domain monomer
igg1
monomer
polypeptide
Prior art date
Application number
JP2021500801A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020014413A5 (https=
JP2021532085A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/041293 external-priority patent/WO2020014413A2/en
Publication of JP2021532085A publication Critical patent/JP2021532085A/ja
Publication of JP2021532085A5 publication Critical patent/JP2021532085A5/ja
Publication of JPWO2020014413A5 publication Critical patent/JPWO2020014413A5/ja
Withdrawn legal-status Critical Current

Links

JP2021500801A 2018-07-11 2019-07-11 ＣＴＬＡ−４を標的とする改変されたＦｃ抗原結合ドメイン構築体に関する組成物および方法 Withdrawn JP2021532085A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862696754P 2018-07-11 2018-07-11
US62/696,754 2018-07-11
US201862743976P 2018-10-10 2018-10-10
US62/743,976 2018-10-10
PCT/US2019/041293 WO2020014413A2 (en) 2018-07-11 2019-07-11 Compositions and methods related to engineered fc-antigen binding domain constructs targeted to ctla-4

Publications (3)

Publication Number Publication Date
JP2021532085A JP2021532085A (ja) 2021-11-25
JP2021532085A5 true JP2021532085A5 (https=) 2022-07-15
JPWO2020014413A5 JPWO2020014413A5 (https=) 2022-07-15

Family

ID=69141692

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021500801A Withdrawn JP2021532085A (ja) 2018-07-11 2019-07-11 ＣＴＬＡ−４を標的とする改変されたＦｃ抗原結合ドメイン構築体に関する組成物および方法

Country Status (11)

Country Link
US (1) US20220064298A1 (https=)
EP (1) EP3820521A4 (https=)
JP (1) JP2021532085A (https=)
KR (1) KR20210044783A (https=)
CN (1) CN113395978A (https=)
AU (1) AU2019301160A1 (https=)
BR (1) BR112021000427A2 (https=)
CA (1) CA3106207A1 (https=)
IL (1) IL280014A (https=)
MX (1) MX2021000306A (https=)
WO (1) WO2020014413A2 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109517059B (zh) 2011-06-30 2023-03-28 中外制药株式会社 异源二聚化多肽
WO2022034920A1 (en) * 2020-08-14 2022-02-17 Chugai Seiyaku Kabushiki Kaisha One-armed antigen-binding molecules and uses thereof
AU2022212978A1 (en) * 2021-01-28 2023-08-31 The Hospital For Sick Children Multabody constructs, compositions, and methods
TWI864408B (zh) * 2021-06-25 2024-12-01 日商中外製藥股份有限公司 抗ctla-4抗體的用途
US12448451B2 (en) 2021-06-25 2025-10-21 Chugai Seiyaku Kabushiki Kaisha Anti-CTLA-4 antibody and use thereof
WO2024212152A1 (en) * 2023-04-13 2024-10-17 Adagene Pte. Ltd. Anti-ctla4 antibodies and methods of making and using the same
EP4731655A1 (en) * 2023-06-23 2026-04-29 CureVac SE Nucleic acid encoded antibodies

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR075989A1 (es) * 2009-04-10 2011-05-11 Lilly Co Eli Anticuerpo dkk -1 (dickkopf-1) humano disenado por ingenieria
EP2948475A2 (en) * 2013-01-23 2015-12-02 AbbVie Inc. Methods and compositions for modulating an immune response
CA2994746A1 (en) * 2015-08-11 2017-02-16 Cellectis Cells for immunotherapy engineered for targeting cd38 antigen and for cd38 gene inactivation
WO2017151971A2 (en) * 2016-03-02 2017-09-08 Momenta Pharmaceuticals, Inc. METHODS RELATED TO ENGINEERED Fc CONSTRUCTS
BR112018074056A2 (pt) * 2016-05-23 2019-03-06 Momenta Pharmaceuticals, Inc. composições e métodos relacionados a construtos de fc manipulados
WO2018035710A1 (en) * 2016-08-23 2018-03-01 Akeso Biopharma, Inc. Anti-ctla4 antibodies
JP6976322B2 (ja) * 2016-10-10 2021-12-08 クラウン バイオサイエンス，インコーポレイテッド（タイツァン） 新規抗ｃｔｌａ４抗体
WO2018089829A1 (en) * 2016-11-10 2018-05-17 Fortis Therapeutics, Inc. Cd46-specific effector cells and uses thereof
CN106913869B (zh) * 2017-03-17 2020-07-28 信达生物制药(苏州)有限公司 一种抗ctla-4单克隆抗体制剂及其应用

Similar Documents

Publication Publication Date Title
JP2021532085A5 (https=)
JP2021530498A5 (https=)
RU2019124709A (ru) КОМПОЗИЦИИ И СПОСОБЫ, СВЯЗАННЫЕ СО СКОНСТРУИРОВАННЫМИ КОНСТРУКЦИЯМИ НА ОСНОВЕ Fc-АНТИГЕНСВЯЗЫВАЮЩЕГО ДОМЕНА
JP2020514301A5 (https=)
JP2021530989A5 (https=)
ES2527961T3 (es) Anticuerpos monoclonales humanos para CD70
JP2021531756A5 (https=)
HRP20201517T1 (hr) Anti-cd3 protutijela, anti-cd123 protutijela i bispecifična protutijela koja se specifično vežu na cd3 i/ili cd123
DE50210328D1 (de) Bispezifisches anti-cd28 antikörper-molekül
RU2011148913A (ru) Иммуноглобулин с двумя вариабельными доменами и его применение
RU2014100111A (ru) МОЛЕКУЛЫ, СВЯЗЫВАЮЩИЕСЯ С Psl Pseudomonas, И ПУТИ ИХ ПРИМЕНЕНИЯ
JP2020508655A5 (https=)
JP2017504578A5 (https=)
RU2007139953A (ru) Антитела к ccr5 и их применение
DE602004021702D1 (de) Humanisierter antikörper gegen cd4 mit immunsuppressiven merkmalen
ATE452147T1 (de) Antikörper mit korrigierten cdr
NZ597168A (en) Dual variable domain immunoglobin and uses thereof
ATE490983T1 (de) Humane antikörper gegen das humane glycoprotein vi und deren verwendung
JP2017513476A5 (https=)
DE602006003695D1 (de) Synthetische Immunoglobulindomänen mit in Regionen des Moleküls, die sich von den die Komplementarität bestimmenden Bereichen unterscheiden, modifizierten Bindeeigenschaften
AU2012325232A8 (en) Stable multiple antigen-binding antibody
JP2021531268A5 (https=)
NZ589434A (en) Dual variable domain immunoglobulins and uses thereof
MX2021004058A (es) Construcciones de anticuerpos que se unen a 4-1bb y a antigenos asociados a tumores y sus usos.
JPWO2020014413A5 (https=)